GlassScriptPhysician profile
Ashleigh E Zacarias
NPI 1508186859
$1,359.72
in general payments reported to CMS, 2019-2025
17 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $279 · 2023: $424 · 2024: $296 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.91 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Exact Sciences Corporation | $162.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $135.06 | 2022-2025 | |
| Abbott Laboratories | $81.90 | 2022-2025 | Eterna, Freestyle Libre 3 |
| Dexcom, INC. | $76.74 | 2024-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $75.80 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $68.79 | 2022-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.52 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $46.15 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $43.21 | 2022-2024 | |
| Axonics, INC. | $33.78 | 2023 | Axonics |
| Glaxosmithkline, LLC. | $31.64 | 2023-2024 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $23.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.75 | 2023 | Synjardy, Tradjenta |
| Phadia US INC. | $20.70 | 2024 | Immunocap |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.91 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $13.21 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Zacarias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.